Immupharma PLC Notification of Change of AGM Venue (5931O)
June 02 2020 - 2:00AM
UK Regulatory
TIDMIMM
RNS Number : 5931O
Immupharma PLC
02 June 2020
RNS: FOR IMMEDIATE RELEASE 2 June 2020
ImmuPharma PLC
("ImmuPharma" or the "Company")
Notification of Change of AGM Venue
ImmuPharma PLC (LSE:IMM), (Euronext Growth Brussels: ALIMM), the
specialist drug discovery and development company announces that
the Company's Annual General Meeting (AGM) confirmed for Thursday,
18 June 2020 @ 10.30am, will now be held at: 52 Grosvenor Garden,
London SW1W 0AU.
The COVID-19 Guidance rules still apply, as set out in the
announcement issued on 21 May 2020, (see Notes to Editors). Any
shareholders attempting to gain access to the AGM will be excluded
from the meeting on the ground of public safety.
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014 ("MAR ").
For further information please contact:
ImmuPharma PLC ( www.immupharma.com )
Tim McCarthy, Chairman + 44 (0) 207 152 4080
Dimitri Dimitriou, Chief Executive Officer
Lisa Baderoon, Head of Investor Relations + 44 (0) 7721 413496
SPARK Advisory Partners Limited (NOMAD)
Neil Baldwin +44 (0 ) 203 36 8 8974
Stanford Capital Partners (Joint Broker)
Patrick Claridge, John Howes +44 (0) 203 815 8880
SI Capital (Joint Broker)
Nick Emerson +44 (0) 1483 413500
4Reliance (Euronext Growth Listing Sponsor) +32 (0) 2 747 02 60
Jean-Charles Snoy
Degroof Petercam (Liquidity Provider) +32 (0) 2 287 95 34
Erik De Clippel
Backstage Communication
Olivier Duquaine +32 (0) 477 504 784
Gunther De Backer +32 (0) 475 903 909
Notes to Editors
About ImmuPharma PLC
ImmuPharma PLC (LSE AIM: IMM - Euronext Growth: ALIMM) is a
specialty biopharmaceutical company that discovers and develops
peptide-based therapeutics. The Company's portfolio includes novel
peptide therapeutics for autoimmune diseases, metabolic diseases,
anti-infectives and cancer. The lead program, Lupuzor(TM), is a
first-in class autophagy immunomodulator which is in Phase III for
the treatment of lupus and preclinical analysis suggest therapeutic
activity for many other autoimmune diseases that share the same
autophagy mechanism of action. ImmuPharma and Avion Pharmaceuticals
signed on 28 November 2019, an exclusive licence and development
agreement and trademark agreement for Lupuzor(TM) to fund a new
international Phase III trial for Lupuzor(TM) and commercialise in
the US. For additional information about ImmuPharma please visit
www.immupharma.com . ImmuPharma's LEI (Legal Entity Identifier)
code: 213800VZKGHXC7VUS895.
COVID-19 Guidance
We note the current issues surrounding COVID-19 (coronavirus)
and the rapidly developing public health guidance in the UK at the
time of writing. This includes the stringent requirements announced
on 23 March 2020, which require UK nationals to stay at home except
in tightly defined circumstances (which do not include attending an
AGM), the social distancing and shielding guidance for those over
the age of 70 or with underlying medical conditions, and the ban on
all non-essential travel. The health and safety of our shareholders
and colleagues is always our utmost priority.
As it is no longer possible to hold the AGM in the way that the
Board had planned, we cannot allow shareholders to attend in
person. Any shareholders attempting to gain access to the AGM will
be excluded from the meeting on grounds of public safety. In the
light of the above, we strongly encourage you to consider ensuring
your vote is counted by submission of the proxy by post as detailed
in the Notice of Annual General Meeting.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NOAEASKFELAEEFA
(END) Dow Jones Newswires
June 02, 2020 02:00 ET (06:00 GMT)
Immupharma (LSE:IMM)
Historical Stock Chart
From Jun 2024 to Jul 2024
Immupharma (LSE:IMM)
Historical Stock Chart
From Jul 2023 to Jul 2024